Skip to main content
Log in

A Risk-Benefit Assessment of Pharmacological and Nonpharmacological Treatments for Nausea and Vomiting of Pregnancy

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Despite evidence of fetal safety, most antiemetics are contraindicated in pregnancy. We summarise a risk-benefit analysis of the literature on safety and effectiveness of pharmacotherapy and nontraditional therapy for nausea and vomiting of pregnancy (NVP) to provide evidence-based guidelines on the management of NVP.

The medical literature was scanned for controlled studies on the human teratogenicity and effect of various antiemetics in pregnant women. Data were pooled based on drug/therapy class and summarised to determine relative risk with 95% confidence interval (for malformations and failure rates for NVP) and homogeneity (chi-square test).

Evidence from controlled trials has demonstrated the safety and efficacy of the following drugs for the treatment of varying degrees of NVP: doxylamine/pyridoxine±dicycloverine (dicyclomine), antihistamine H1 receptor antagonists, and phenothiazines (as a group). However, pooled data for doxylamine/ pyridoxine±dicycloverine, H1 antagonists and phenothiazines were not homogeneous. Other therapies, such as pyridoxine alone, metoclopramide, ondansetron and the corticosteroids may be beneficial in managing NVP. However, limited efficacy studies and the paucity of well-controlled safety studies may limit the use of some of these agents among patients not responsive to first-line agents. Well-controlled safety and effectiveness trials in patients with NVP are lacking for nonpharmacological treatments (e.g. acupressure).

NVP can be managed safely and effectively. Further trials must be conducted in order to determine the true effectiveness of certain agents in patients with NVP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Table II

Similar content being viewed by others

References

  1. Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract 1993; 43: 245–8

    PubMed  CAS  Google Scholar 

  2. Vellacott ID, Cooke EJA, James CE. Nausea and vomiting in early pregnancy. Int J Gynecol Obstet 1988; 27: 57–62

    CAS  Google Scholar 

  3. De la Ronde SK. Nausea and vomiting in pregnancy. J Soc Obstetricians Gynaecologists Can 1994; 16: 2035–41

    Google Scholar 

  4. Depue RH, Bernstein L, Ross RK, et al. Hyperemesis gravidarum in relation to estroadiol levels, pregnancy outcome, and other maternal factors: a seroepidemiologic study. Am J Obstet Gynecol 1987; 157: 1137–41

    Google Scholar 

  5. Kimura M, Amino N, Tamakai H, et al. Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of HCG with higher stimulating activity. Clin Endocrinol (Oxf) 1993; 38: 345–50

    CAS  Google Scholar 

  6. Wilson R, McKillop JH, MacLean M, et al. Thyroid function tests are rarely abnormal in patients with severe hyperemesis gravidarum. Clin Endocrinol (Oxf) 1992; 37: 331–4

    CAS  Google Scholar 

  7. Shulman A, Shapiro MS, Bahary C, et al. Abnormal thyroid function in hyperemesis gravidarum. Acta Obstet Gynecol Scand 1989; 68: 533–6

    PubMed  CAS  Google Scholar 

  8. Jeffcoate WJ. Recurrent pregnancy-induced thyrotoxicosis presenting as hyperemesis gravidarum: case report. Br J Obstet Gynaecol 1985; 92: 413–5

    PubMed  CAS  Google Scholar 

  9. Koch KL, Stern RM, Vasey M, et al. Gastric dysrhythmias and nausea of pregnancy. Dig Dis Sci 1990; 35(8): 961–8

    PubMed  CAS  Google Scholar 

  10. Deuchar N. Nausea and vomiting in pregnancy: a review of the problem with particular regard to psychological and social aspects. Br J Obstet Gynaecol 1995; 102: 6–8

    PubMed  CAS  Google Scholar 

  11. Callahan E, Burnett M, DeLawyer D, et al. Behavioural treatment of hyperemesis gravidarum. J Psychosomat Obstet Gynecol 1986; 5: 187–96

    Google Scholar 

  12. Malagelada JR, Camilleri M. Unexplained vomiting: a diagnostic challenge. Ann Intern Med 1984; 101: 211–8

    PubMed  CAS  Google Scholar 

  13. Einarson TR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm 1988; 22: 813–23

    PubMed  CAS  Google Scholar 

  14. Newman V, Fullerton JT, Anderson PO. Clinical advances in the management of severe nausea and vomiting during pregnancy. J Obstet Gynecol Neonatal Nurs 1993; 22: 483–90

    PubMed  CAS  Google Scholar 

  15. Shaw J, Brooks PM, McNeil JJ, et al. The management of nausea and vomiting during pregnancy. Med J Aust 1987; 147: 290–1

    Google Scholar 

  16. de la Ronde S, Thirsk J, the SOGC Clinical Practice — Obstetrics Committee. Committee opinion: guidelines for the management of nausea and vomiting in pregnancy. J Soc Obstetricians Gynaecologists Can 1996; 18(3): 255–7

    Google Scholar 

  17. Jewell D, Young G. Treatments for nausea and vomiting in early pregnancy. In: Neilson JP, Crowther CA, Hodnett ED, et al., editors. Pregnancy and childbirth module of The Cochrane Database of Systematic Reviews, [updated 04 March 1997]. Available in The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration; Issue 2. Oxford: Update Software; 1997. Updated quarterly

    Google Scholar 

  18. Briggs GG, Freeman RK, Yaffe SJ, editors. Drugs in pregnancy and lactation. 5th ed. Baltimore: Williams and Wilkins, 1998

    Google Scholar 

  19. O’Brien B, Naber S. Nausea and vomiting during pregnancy: effects on the quality of women’s lives. Birth 1992; 19(3): 138–43

    PubMed  Google Scholar 

  20. Erick M. Battling morning (noon and night) sickness: new approaches for treating an age-old problem. J Am Diet Assoc 1994; 94: 147–8

    PubMed  CAS  Google Scholar 

  21. Tufts University Diet and Nutrition Letter 1994; 11 (1): 6–7

  22. General Practitioner Research Group. General practioner clinical trials: drugs in pregnancy survey. Practitioner 1963; 191: 775–80

    Google Scholar 

  23. Bunde CA, Bowles DM. A technique for controlled survey of case records. Curr Ther Res 1963; 5: 245–8

    PubMed  CAS  Google Scholar 

  24. Greenberg G, Inman WHW, Weatherall JAC, et al. Maternal drug histories and congenital abnormalities. BMJ 1977; 2: 853–6

    PubMed  CAS  Google Scholar 

  25. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977

    Google Scholar 

  26. Newman NM, Correy JF, Dudgeon GI. A survey of congenital abnormalities and drugs in private practice. N Z J Obstet Gynecol 1977; 17: 156–9

    Google Scholar 

  27. Smithells RW, Sheppard S. Teratogenicity testing in humans: a method demonstrating safety of Bendectin. Teratology 1978; 17: 31–5

    PubMed  CAS  Google Scholar 

  28. Michaelis J, Gluck E, Michaelis H, et al. Does Lenotan have teratogenic effects? Dtsh Arztedl 1980; 23: 1527–9

    Google Scholar 

  29. Jick H, Holmes LB, Hunter JR, et al. First-trimester drug use and congenital disorders. JAMA 1981; 246(4): 343–6

    PubMed  CAS  Google Scholar 

  30. Fleming DM, Knox JDE, Crombie DL. Debendox in early pregnancy and fetal malformation. BMJ 1981; 283: 99–101

    PubMed  CAS  Google Scholar 

  31. Gibson GT, Colley DP, McMichael AJ, et al. Congenital anomalies in relation to the use of doxylamine/dicyclomine and other antenatal factors. Med J Aust 1981; 1: 410–4

    PubMed  CAS  Google Scholar 

  32. Eskenazi B, Bracken MB. Bendictin (Debendox) as a risk factor for pyloric stenosis. Am J Obstet Gynecol 1982; 144: 919–24

    PubMed  CAS  Google Scholar 

  33. Morelock S, Hingson R, Kayne H, et al. Bendectin and fetal development. Am J Obstet Gynecol 1982; 142: 209–13

    PubMed  CAS  Google Scholar 

  34. Aselton P, Jick H, Milunsky A, et al. First-trimester drug use and congenital disorders. Obstet Gynecol 1985; 65(4): 451–5

    PubMed  CAS  Google Scholar 

  35. Shiono PH, Klebanoff MA. Bendectin and human congenital malformations. Teratology 1989; 40: 151–5

    PubMed  CAS  Google Scholar 

  36. Erikson JD. Risk factors for birth defects: data from the Atlanta Birth Defects Case-Control Study. Teratology 1991; 43: 41–51

    Google Scholar 

  37. McKeigne PM, Lam SH, Linn S, et al. Bendectin® and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology 1994; 50: 27–37

    Google Scholar 

  38. Geiger CJ, Fahrenbach DM, Healey FJ. Bendectin® in the treatment of nausea and vomiting in pregnancy. Obstet Gynecol 1959; 14: 688–90

    PubMed  CAS  Google Scholar 

  39. McGuinness BW, Taylor Binns D. ‘Debendox’ in pregnancy sickness. J R Coll Gen Pract 1971; 21: 500–3

    PubMed  CAS  Google Scholar 

  40. Wheatley D. Treatment of pregnancy sickness. Br J Obstet Gynaecol 1977; 84: 444–7

    PubMed  CAS  Google Scholar 

  41. Bendectin Peer Group. Bio/Basics International Peer Group Report. Merrell Dow Pharmaceuticals Inc., March 14, 1975: 559–637

  42. Cartwright EW. Dramamine in nausea and vomiting of pregnancy. West J Surg 1951; 59: 216–34

    PubMed  CAS  Google Scholar 

  43. King AG. The treatment of pregnancy nausea with a pill. Obstet Gynecol 1955; 6: 332–8

    PubMed  CAS  Google Scholar 

  44. Conklin FJ, Nesbitt REL. Buclizine hydrochloride for nausea and vomiting of pregnancy. Obstet Gynecol 1958; 11: 214–9

    PubMed  CAS  Google Scholar 

  45. Diggory PLC, Tomkinson JS. Nausea and vomiting in pregnancy. A trial of meclozine dihydrochloride with and without pyridoxine. Lancet 1962; II: 370–2

    Google Scholar 

  46. Baum G, Boxer EL, Davidson JH, et al. Meclozine and pyridoxine in pregnancy sickness. Practitioner 1963; 190: 251–3

    Google Scholar 

  47. Erez S, Schifrin BS, Dirim O. Double-blind evaluation of hydroxyzine as an antiemetic in pregnancy. J Reprod Med 1971; 7: 57–9

    Google Scholar 

  48. Lask S. Treatment of nausea and vomiting of pregnancy with anti-histamines. BMJ 1953; 1: 652–3

    PubMed  CAS  Google Scholar 

  49. Fitzgerald JPB. The effect of promethazine in nausea and vomiting of pregnancy. N Z Med J 1955; 54: 215–8

    PubMed  CAS  Google Scholar 

  50. Newlinds JS. Nausea and vomiting in pregnancy: a trial of triethylperazine. Med J Aust 1964; 51: 234–6

    Google Scholar 

  51. Winters HS. Anti-emetics in nausea and vomiting of pregnancy. Obstet Gynecol 1961; 18: 753–6

    PubMed  CAS  Google Scholar 

  52. Sahakian V, Rouse D, Sipes S, et al. Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: a randomized, double-blind placebo-controlled study. Obstet Gynecol 1991; 78: 33–6

    PubMed  CAS  Google Scholar 

  53. Vutyavanich T, Wongtra-ngan S, Ruangsri R. Pyridoxine for nausea and vomiting of pregnancy: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1995; 173: 881–4

    PubMed  CAS  Google Scholar 

  54. Ylikorkala O, Kauppila A, Ollanketo ML. Intramuscular ACTH and placebo in the treatment of hyperemesis gravidarum. Acta Obstet Gynecol Scand 1979; 58: 453–5

    PubMed  CAS  Google Scholar 

  55. Safari HR, Fassett MJ, Souter IC, et al. The efficacy of methyl-prednisolone in the treatment of hyperemesis gravidarum: a randomized, double-blind, controlled study. Am J Obstet Gynecol 1998; 179: 921–4

    PubMed  CAS  Google Scholar 

  56. Czeizel AE, Dudas I, Fritz G, et al. The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. Arch Gynecol Obstet 1992; 251: 181–5

    PubMed  CAS  Google Scholar 

  57. Schatz M, Petitti D. Anti-histamines and pregnancy. Ann Allergy Asthma Immunol 1997; 78: 157–9

    PubMed  CAS  Google Scholar 

  58. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to anti-histamines: meta-analysis. Am J Perinatal 1997; 14(3): 119–24

    CAS  Google Scholar 

  59. Mellin GW, Katzenstein M. Meclozine and foetal abnormalities. Lancet 1963; 26: 222–3

    Google Scholar 

  60. Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. BMJ 1971; 1: 523–7

    PubMed  CAS  Google Scholar 

  61. Saxen I. Cleft palate and maternal diphenhydramine intake. Lancet 1974; I: 407–8

    Google Scholar 

  62. Kullander S, Kallen B. A prospective study of drugs and pregnancy. II. Anti-emetic drugs. Acta Obstet Gynecol Scand 1976; 55: 105–11

    CAS  Google Scholar 

  63. Mitchell AA, Schwingl PJ, Rosenberg L, et al. Birth defects in relation to Bendectin® use in pregnancy. II. Pyloric stenosis. Am J Obstet Gynecol 1983; 147(7): 737–42

    CAS  Google Scholar 

  64. Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann All Asthma Immunol 1997; 78: 183–6

    CAS  Google Scholar 

  65. Milkovich L, Van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 1976; 125: 244–8

    PubMed  CAS  Google Scholar 

  66. American Hospital Formulary Service. Drug Information 1990. Bethesda (MD): American Society of Hospital Pharmacists, 1990: 2116–8

    Google Scholar 

  67. Gant H, Reinken L, Dapunt O, et al. Vitamin B6 depletion in women with hyperemesis gravidarum. Wien Klin Wochenschr 1975; 87: 510–7

    PubMed  CAS  Google Scholar 

  68. Willis DM, O’Grady JP, Faber JJ, et al. Diffusion of permeability of cyanocobalamin in human placenta. Am J Physiol 1986; 250 (3 Pt 2): R459–64

    PubMed  CAS  Google Scholar 

  69. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345: 149–51

    PubMed  CAS  Google Scholar 

  70. Ho CK, Kaufman RL, McAlister WH. Congenital malformations. Cleft palate, congenital heart disease, absent tibiae, and polydactyly. Am J Dis Child 1975; 129: 714–6

    CAS  Google Scholar 

  71. Farag RA, Ananth J. Thanatophoric dwarfism associated with prochlorperazine administration. N Y State J Med 1978; 78: 279–82

    Google Scholar 

  72. Freeman R. Limb deformities: possible association with drugs. Med J Aust 1972; 1: 606–7

    PubMed  CAS  Google Scholar 

  73. Hall G. A case of phocomelia of the upper limbs. Med J Aust 1963; 1: 449–50

    Google Scholar 

  74. Rafla N. Limb deformities associated with prochlorperazine [letter]. Am J Obstet Gynecol 1987; 156: 1557

    PubMed  CAS  Google Scholar 

  75. Brambati B, Lanzani A, Sanchioni L, et al. Conjoined twins and in utero early exposure to prochlorperazine. Reprod Toxicol 1990; 4: 331–2

    PubMed  CAS  Google Scholar 

  76. Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1976; 15: 57–64

    Google Scholar 

  77. Moriarty AJ, Nance MR. Trifluoperazine and pregnancy. Can Med Ass J 1963; 88: 375–6

    PubMed  CAS  Google Scholar 

  78. Shepard TH. Catalog of teratogenic agents. 7th ed. Baltimore (MD): John Hopkins University Press, 1992

    Google Scholar 

  79. Nageotte MP, Briggs GC, Towers CV, et al. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. Am J Obstet Gynecol 1996; 174(6): 1801–6

    PubMed  CAS  Google Scholar 

  80. Brunton LL. Agents affecting gastrointestinal water flux and motility; emesis and antiemetics; bile acids and pancreatic enzymes. In: Hartman JG, Gilman AG, Limbird LE, editors. The pharmacological basis of therapeutics. 9th ed. New York (NY): McGraw-Hill 1996: 917–36

    Google Scholar 

  81. Einarson A, Koren G, Bergman U. The treatment of nausea and vomiting in pregnancy. Eur J Obstet Gynecol Reprod Biol 1998; 76(1): 1–3

    PubMed  CAS  Google Scholar 

  82. Sidhu MS, Lean TH. The use of metoclopramide (Maxolon) in hyperemesis gravidarum. Proc Obstet Gynaecol Soc Singapore 1970; 1: 43–6

    Google Scholar 

  83. Pinder RM, Brogden RN, Sawyer PR, et al. Metoclopramide, a review of its pharmacological properties. Drugs 1976; 12: 81–131

    PubMed  CAS  Google Scholar 

  84. Tucker ML, Jackson MR, Scales MDC, Ondansetron: pre-clinical safety evaluation. Eur J Cancer Clin Oncol 1989; 25 Suppl. 1: S79–S93

    PubMed  Google Scholar 

  85. Guikontes E, Spantideas A, Kiakakis J. Ondansetron and hyperemesis gravidarum [letter]. Lancet 1992; 340: 1223

    PubMed  CAS  Google Scholar 

  86. World MJ. Ondansetron and hyperemesis gravidarum [letter]. Lancet 1993; 341: 185

    PubMed  CAS  Google Scholar 

  87. Tincello DG, Johnstone MJ. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). Postgrad Med J 1996; 72(853): 688–9

    PubMed  CAS  Google Scholar 

  88. Sullivan CA, Johnson CA, Roach H, et al. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 1996; 174(5): 1565–8

    PubMed  CAS  Google Scholar 

  89. Bailey B, Addis A, Lee A, et al. Cisapride use during human pregnancy: a prospective controlled study. Dig Dis Sci 1997; 42(9): 1848–52

    PubMed  CAS  Google Scholar 

  90. Wells CN. Treatment of hyperemesis gravidarum with cortisone. Am J Obstet Gynecol 1953; 66: 598–601

    PubMed  CAS  Google Scholar 

  91. Parry H, Martin K. Single dose iv dexamethasone: an effective anti-emetic in cancer chemotherapy. Cancer Chem Pharmacol 1991; 28: 231–2

    CAS  Google Scholar 

  92. Fainstat T. Cortisone-induced congenital cleft palate in rabbits. Endocrinology 1954; 55: 502

    PubMed  CAS  Google Scholar 

  93. Mogadam M, Dobbins WO, Korelitz BI, et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroid on fetal outcome. Gastroenterology 1981; 80(1): 72–6

    PubMed  CAS  Google Scholar 

  94. Popert AJ. Pregnancy and adrenocortical hormones. BMJ 1962: 967–72

  95. Warrell DW, Taylor R. Outcome for the fetus of mothers receiving prednisolone during pregnancy. Lancet 1968; I(534): 117–8

    Google Scholar 

  96. Mintz G, Niz J, Gutierrez G, et al. Prospective study of pregnancy in systemic lupus erythermatosus. Results of a multi-disciplinary approach. J Rheumatol 1986; 13(4): 732–9

    CAS  Google Scholar 

  97. Jacobson SJ, Pastuszak A, Koren G. Effects of prenatal exposure to prednisone; a prospective study [abstract]. Ped Research 1997; 41 (4 Pt 2): 348A

    Google Scholar 

  98. Czeizel C, Rockenbauer M. Population-based case-control study of teratogenic potential of corticosteroids. Teratology 1997; 56: 335–40

    PubMed  CAS  Google Scholar 

  99. Richards ID. A retrospective inquiry into possible teratogenic effects of drugs in pregnancy. Drugs Teratol Dev 1971: 441–55

  100. Park-Wyelie L, Mazzotta P, Pastuszak A, et al. Birth defects following maternal exposure to corticosteroids: a prospective cohort study, and a meta-analysis of epidemiological studies. Teratology. In press

  101. Robert E, Vollset SE, Botto L, et al. Malformation surveillance and maternal drug exposure: the MADRE project. Int J Risk Saf Med 1994; 6: 75–118

    Google Scholar 

  102. Rodriguez-Pinilla E, Martinez-Firas ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 1998; 58: 2–5

    PubMed  CAS  Google Scholar 

  103. Taylor R. Successful management of hyperemesis gravidarum using steroid therapy. Q J Med 1996; 89(2): 103–7

    CAS  Google Scholar 

  104. Nelson-Piercy C, de Swiet M. Corticosteroids for the treatment of hyperemesis gravidarum. Br J Obstet Gynecol 1994; 101: 1013–5

    CAS  Google Scholar 

  105. Nelson-Piercy C, de Sweit M. Complications of the use of corticosteroids for the treatment of hyperemesis gravidarum. Br J Obstet Gynecol 1995; 102: 507–9

    Google Scholar 

  106. Magee LA, Redman CWG. An N-of-1 trial for treatment of hyperemesis gravidarum. Br J Obstet Gynecol 1996; 103: 478–80

    CAS  Google Scholar 

  107. Fischer-Rasmussen W, Kjaer SK, Dahl C, et al. Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol 1990; 38: 19–24

    Google Scholar 

  108. Sallan SE, Zinberg NE, Frei E. Anti-emetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293: 795–7

    PubMed  CAS  Google Scholar 

  109. Chang AE, Shiling DJ, Stillman RC, et al. Delta-9-tetrahyrdocannibinol as an anti-emetic in cancer patients receiving high dose methotrexate; a prospective randomized evaluation. Ann Intern Med 1979; 91: 819–24

    PubMed  CAS  Google Scholar 

  110. Ekert K, Waters KD, Jurk IH. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetra-hydrocannbinol. Med J Aust 1979; 2: 657–9

    PubMed  CAS  Google Scholar 

  111. De Aloysio D, Penacchioni P. Morning sickness control in early pregnancy by Neiguan point acupressure. Obstet Gynecol 1992; 80: 852–4

    PubMed  Google Scholar 

  112. Dundee JW, Sourial FBR, Ghaly RG, et al. P6 acupressure reduces morning sickness. J R Soc Med 1988; 81: 456–7

    PubMed  CAS  Google Scholar 

  113. Hyde E. Acupressure therapy for morning sickness: a controlled clinical trial. J Nurse Midwifery 1989; 34(4): 171–8

    PubMed  CAS  Google Scholar 

  114. Belluomini J, Litt RC, Lee KA, et al. Acupressure for nausea and vomiting of pregnancy: a randomized, blinded study. Obstet Gynecol 1994; 84: 245–8

    PubMed  CAS  Google Scholar 

  115. O’Brien B, Relyea MJ, Taerum T. Efficacy of P6 acupressure in the treatment of nausea and vomiting during pregnancy. Am J Obstet Gynecol 1996; 174: 708–15

    PubMed  Google Scholar 

  116. Evans AT, Samuels SN, Marshall C, et al. Suppression of pregnancy-induced nausea and vomiting with sensory afferent stimulation. J Reprod Med 1993; 38(8): 603–6

    PubMed  CAS  Google Scholar 

  117. Bayreuther J, Lewith GT, Pickering R. A double-blind crossover study to evaluate the effectiveness of acupressure at pericardium 6 (P6) in the treatment of early morning sickness (EMS). Complement Ther Med 1994; 2: 70–6

    Google Scholar 

  118. Kroger W, DeLee S. The psychosomatic treatment of hyperemesis gravidarum by hypnosis. Am J Obstet Gynecol 1946; 51: 544–52

    PubMed  CAS  Google Scholar 

  119. Giorlando S, Mascola R. The treatment of hyperemesis gravidarum with hypnotherapy. Am J Obstet Gynecol 1957; 73: 444–7

    PubMed  CAS  Google Scholar 

  120. Henker III FO. Psychotherapy as adjunct in treatment of vomiting during pregnancy. South Med J 1976; 69(12): 1585–7

    PubMed  Google Scholar 

  121. Smallwood RA, Berlin RG, Castagnoli N, et al. Safety of acid-suppressing drugs. Dig Dis Sci 1995; 40 Suppl. 2: 63S–80S

    PubMed  CAS  Google Scholar 

  122. Dordevic M, Beric B. Our experience in the treatment of pyrosis in pregnancy with Kompensan. Med Preg 1972; 25: 277–9

    CAS  Google Scholar 

  123. Jacobs D. Maternal drug ingestion and congenital malformations. S Afr Med J 1975; 49: 2073–80

    PubMed  CAS  Google Scholar 

  124. Lewis JH, Weingold AAB. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol 1985; 80: 912–23

    PubMed  CAS  Google Scholar 

  125. Jones DGC, Langman MJS, Lawson DH, et al. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Q J Med 1985; 54(215): 253–68

    Google Scholar 

  126. Magee LA, Inocencion G, Kamboj L, et al. Safety of first trimester exposure to histamine H2-blockers: a prospective cohort study. Dig Dis Sci 1996; 41(6): 1145–9

    PubMed  CAS  Google Scholar 

  127. Lalkin A, Loebstein R, Addis A, et al. Safety of omeprazole during pregnancy: a multi-centre prospective cohort study. Am J Obstet Gynecol. 1998 Sep; 179 (3 Pt 1): 727–30

    PubMed  CAS  Google Scholar 

  128. Schardein JL, Furuhashi T, Ooshima Y. Reproductive and developmental toxicology studies of lansoprazole (AG-1749) in rats and rabbits. Yakuri Chiryo 1990; 18 (Suppl. 10): 119–29

    Google Scholar 

  129. Koren G, Bologa M, Long D, et al. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first-trimester. Am J Obstet Gynecol 1989; 160(5): 1190–4

    PubMed  CAS  Google Scholar 

  130. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. New Engl J Med 1998; 338(16): 1128–37

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Special thanks to Dr Benoit Bailey, Dr Peter von Dadelszen and Dr Gideon Koren for their valuable clinical input into the preparation of this paper. This paper was partially funded by the Motherisk Research Grant. Motherisk receives an annual educational grant from Duchesnay, Incorporated.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Laura A. Magee.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazzotta, P., Magee, L.A. A Risk-Benefit Assessment of Pharmacological and Nonpharmacological Treatments for Nausea and Vomiting of Pregnancy. Drugs 59, 781–800 (2000). https://doi.org/10.2165/00003495-200059040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059040-00005

Keywords

Navigation